iBio, Inc. (IBIO)
0.7823
+0.01
(+1.77%)
USD |
NASDAQ |
Nov 02, 16:00
0.7853
0.00 (0.00%)
After-Hours: 18:47
iBio Enterprise Value : -43.03M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -43.03M |
| October 29, 2026 | -40.52M |
| October 28, 2026 | -41.05M |
| October 27, 2026 | -43.13M |
| October 26, 2026 | -46.46M |
| October 23, 2026 | -45.86M |
| October 22, 2026 | -42.17M |
| October 21, 2026 | -39.05M |
| October 20, 2026 | -40.11M |
| October 19, 2026 | -43.50M |
| October 16, 2026 | -43.16M |
| October 15, 2026 | -42.24M |
| October 14, 2026 | -42.35M |
| October 13, 2026 | -42.30M |
| October 12, 2026 | -35.53M |
| October 09, 2026 | -37.33M |
| October 08, 2026 | -34.60M |
| October 07, 2026 | -29.59M |
| October 06, 2026 | -27.36M |
| October 05, 2026 | -23.46M |
| October 02, 2026 | -23.18M |
| October 01, 2026 | -24.02M |
| September 30, 2026 | -20.12M |
| September 29, 2026 | -20.67M |
| September 28, 2026 | -20.67M |
| Date | Value |
|---|---|
| September 25, 2026 | -19.56M |
| September 24, 2026 | -19.00M |
| September 23, 2026 | -16.50M |
| September 22, 2026 | -11.76M |
| September 21, 2026 | -15.66M |
| September 18, 2026 | -14.55M |
| September 17, 2026 | -16.22M |
| September 16, 2026 | -20.12M |
| September 15, 2026 | -19.56M |
| September 14, 2026 | -19.00M |
| September 11, 2026 | -18.72M |
| September 10, 2026 | -17.61M |
| September 09, 2026 | -15.66M |
| September 08, 2026 | -13.43M |
| September 04, 2026 | -12.88M |
| September 03, 2026 | -13.43M |
| September 02, 2026 | -12.88M |
| September 01, 2026 | -15.66M |
| August 31, 2026 | -15.10M |
| August 28, 2026 | -10.09M |
| August 27, 2026 | -7.863M |
| August 26, 2026 | -6.192M |
| August 25, 2026 | -3.964M |
| August 24, 2026 | -6.749M |
| August 21, 2026 | -6.192M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
| Savara, Inc. | 847.40M |
| Vericel Corp. | 1.992B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.60M |
| Total Expenses (Quarterly) | 10.60M |
| EPS Diluted (Quarterly) | -0.1903 |
| Earnings Yield | -57.98% |
| Normalized Earnings Yield | -53.85 |